TI
SYRE icon

Trexquant Investment’s Spyre Therapeutics SYRE Stock Holding History

Trexquant Investment’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Buy
+67,007
New +$4.89M 0.04% 659
2021
Q1 		– Sell
-805
Closed -$158K – 1453
2020
Q4 		$158K Buy
+805
New +$167K 0.02% 928
2020
Q3 		– Sell
-547
Closed -$126K – 1522
2020
Q2 		$126K Buy
+547
New +$104K 0.01% 1105
2019
Q1 		– Sell
-618
Closed -$116K – 1304
2018
Q4 		$116K Buy
+618
New +$131K 0.01% 982

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Trexquant Investment's SYRE Position: Q2 2026 in Review

Trexquant Investment opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 67,007 shares worth $5.95M. The stake represents 0.04% of the portfolio and ranks #659 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in SYRE as recently as Q4 2020.

Trexquant Investment first reported a position in SYRE in Q4 2018 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Trexquant Investment held 67,007 shares of Spyre Therapeutics worth $5.95M as of Q2 2026.
  • Spyre Therapeutics was a new Trexquant Investment position in Q2 2026.
  • Spyre Therapeutics made up 0.04% of Trexquant Investment's portfolio in Q2 2026, its #659 holding.
  • Trexquant Investment first reported a position in Spyre Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.